Clinical Trials

Showing trials with last updates posted in 2026.

NCT03801434 | ACTIVE_NOT_RECRUITING | PHASE2
8 participants

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-01
Start Date:
2019-11-15
Completion:
2029-02-28
Conditions
  • BCR-JAK2 Fusion Protein Expression
  • Blasts 20 Percent or Less of Peripheral Blood White Cells
  • Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
  • Blasts More Than 5 Percent of Peripheral Blood White Cells
  • Blasts Under 20 Percent of Bone Marrow Nucleated Cells
  • Chronic Eosinophilic Leukemia, Not Otherwise Specified
  • Eosinophilia
  • Hepatomegaly
  • Hypereosinophilic Syndrome
  • JAK2 Gene Mutation
  • Splenomegaly
  • TEL-JAK2 Fusion Protein Expression
Interventions
  • DRUG
No Results Yet
NCT03604991 | SUSPENDED | PHASE2/PHASE3
278 participants

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-01
Start Date:
2019-05-03
Completion:
2026-12-31
Conditions
  • Clinical Stage II Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage III Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8
  • Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Esophageal Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
  • RADIATION
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page